Document:

Exhibit 10(a)

                        ADDENDUM TO EMPLOYMENT AGREEMENT

     THIS  ADDENDUM  TO  EMPLOYMENT  AGREEMENT  (this  "Addendum"),   dated  and
effective this 26th day of April, 2005, is by and between FIRST BANCORP, a North
Carolina corporation (the "Company") and James H. Garner (the "Employee").  This
Addendum is intended as a supplement and amendment to the  Employment  Agreement
dated and effective as of August 17, 1998 (the  "Employment  Agreement")  by and
between the Company and the  Employee.  Unless the context  requires  otherwise,
each term used herein that is defined in the Employment Agreement shall have the
meaning  assigned to such term in the  Employment  Agreement.  Each reference to
"hereof",  "hereunder",  "herein" and "hereby" and each other similar  reference
and  each  reference  to  "this  Agreement"  and each  other  similar  reference
contained in the Employment Agreement shall from and after the date hereof refer
to the Employment Agreement as amended hereby.

     For and in  consideration  of the above  premises  and  agreements,  and in
consideration  of  employment,  the  compensation  the Company agrees to pay the
Employee, the mutual covenants contained herein, and for other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties mutually
agree as follows:

     1. Section 3 of the Employment Agreement is amended by adding the following
subparagraphs:

     (e) Death Benefit.  Upon the death of the Employee and upon presentation of
         -------------
     a death certificate to the Company, the Company will make a cash payment of
     $100,000 to the  Employee's  estate or to such  beneficiary as the Employee
     shall specify to the Company by providing  written  notice under the notice
     provisions of this Employment Agreement.

     (f) Upon the Employee's retirement hereunder, the Company agrees to provide
     one of the following  two benefits,  at the option of the Company - 1) make
     monthly payments to Employee and Employee's  spouse,  for so long as either
     Employee or Employee's spouse shall survive, in an amount equal to the then
     monthly cost of the Plan J Medicare  supplement  coverage  provided by Blue
     Cross and Blue Shield of North  Carolina or, at the Company's  option,  the
     monthly cost of a different Medicare supplement plan with benefits equal to
     or comparable to the current  benefits  provided by such Plan J, or 2) make
     premium  payments  directly  to an  insurance  carrier to provide  Medicare
     supplement  coverage  equal to, or  comparable  to,  the  current  benefits
     offered  under  Plan J  provided  by Blue  Cross  and Blue  Shield of North
     Carolina for Employee and Employee's spouse, for so long as either Employee
     or Employee's spouse shall survive.

<PAGE>

     2.  Section  11(e) is  amended  by adding  the  following  address  for the
Employee:

         James H. Garner
         116 Garner Britt Drive
         Robbins, NC  27325

     3.  Except as set forth expressly  hereinabove, all terms of the Employment
Agreement shall be and remain in full force and effect and shall  constitute the
legal,  valid,  binding and  enforceable  obligations  of the  Employee  and the
Company.  The amendments  contained  herein shall be deemed to have  prospective
application only, unless otherwise specifically stated herein.

     4. This  Addendum  shall be governed by and construed  and  interpreted  in
accordance with the laws of the State of North Carolina.

     IN WITNESS  WHEREOF,  the parties  hereto have executed this Addendum as of
the day and year first above stated.

                                  FIRST BANCORP

                                  By: /s/ Anna G. Hollers
                                  Name: Anna G. Hollers
                                  Title: Secretary and Executive Vice President

                                  EMPLOYEE

                                  /s/ James H. Garner
                                  James H. Garner

                                       2EXHIBIT 10

                          CONSENT OF ERNST & YOUNG LLP,
                  INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

         We consent to the references to our firm under the caption "Financial
Highlights" and "Independent Registered Public Accounting Firm" in the
Prospectus, and "Independent Public Accountants" and "Financial Statements" in
the Statement of Additional Information and to the use of our report dated March
10, 2005, with respect to the financial statements of PAX World Balanced Fund,
Inc., PAX World Growth Fund, Inc. and PAX World High Yield Fund, Inc. included
in their Annual Report dated December 31, 2004 that is incorporated by reference
into this Post-Effective Amendment Number 7 to the Registration Statement (Form
N-1A No. 333-23549) of PAX World Growth Fund, Inc.

                                                /s/  ERNST & YOUNG LLP
                                                     -----------------
                                                     ERNST & YOUNG LLP

Boston, Massachusetts
April 25, 2005EXHIBIT 10(b)

                             PANNELL KERR FORSTER PC
                          Certified Public Accountants
                               265 Franklin Street
                                Boston, MA 02110

               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Shareholders and the Board of Directors
of Pax World Growth Fund, Inc.

         We consent (i) to the incorporation by reference and use in
Post-Effective Amendment No. 7 to Registration Statement No. 333-23549 of Pax
World Growth Fund, Inc. on Form N-1A of our reports for the fiscal years ended
December 31, 2000 through 2002, inclusive, with respect to the financial
statements of Pax World Balanced Fund, Inc., Pax World Growth Fund, Inc. and Pax
World High Yield Fund, Inc. and (ii) to the reference to us (A) under the
headings "Financial Highlights" in the Prospectus, and (B) under the headings
"Investment Advisory and Other Services - Independent Public Accountants" and
"Financial Statements" in the Statement of Additional Information.

                                                /s/  PANNELL KERR FORSTER PC
                                                     -----------------------
                                                     PANNELL KERR FORSTER PC

Boston, Massachusetts
April 29, 2005EXHIBIT 10(a)

                          CONSENT OF ERNST & YOUNG LLP,
                  INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

         We consent to the references to our firm under the caption "Financial
Highlights" and "Independent Registered Public Accounting Firm" in each
Prospectus, and "Independent Public Accountants" and "Financial Statements" in
the Statement of Additional Information and to the use of our report dated March
10, 2005, with respect to the financial statements of PAX World Balanced Fund,
Inc., PAX World Growth Fund, Inc. and PAX World High Yield Fund, Inc. included
in their Annual Report dated December 31, 2004 that is incorporated by reference
into this Post-Effective Amendment Number 7 to the Registration Statement (Form
N-1A No. 333-82133) of PAX World High Yield Fund, Inc.

                                                /s/  ERNST & YOUNG LLP
                                                     -----------------
                                                     ERNST & YOUNG LLP

Boston, Massachusetts
April 25, 2005EXHIBIT 10(b)

                             PANNELL KERR FORSTER PC
                          Certified Public Accountants
                               265 Franklin Street
                                Boston, MA 02110

               CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

To the Shareholders and the Board of Directors
of Pax World High Yield Fund, Inc.

         We consent (i) to the incorporation by reference and use in
Post-Effective Amendment No. 7 to Registration Statement No. 333-82133 of Pax
World High Yield Fund, Inc. on Form N-1A of our reports for the fiscal years
ended December 31, 2000 through 2002, inclusive, with respect to the financial
statements of Pax World Balanced Fund, Inc., Pax World Growth Fund, Inc. and Pax
World High Yield Fund, Inc. and (ii) to the reference to us (A) under the
headings "Financial Highlights" in both Prospectuses, and (B) under the headings
"Investment Advisory and Other Services - Independent Public Accountants" and
"Financial Statements" in the Statement of Additional Information.

                                                     /s/ PANNELL KERR FORSTER PC
                                                         -----------------------
                                                         PANNELL KERR FORSTER PC

Boston, Massachusetts
April 29, 200510Q Q3 2005 EXHIBIT 10.1

Exhibit 10.1

FIRST AMENDMENT TO PATENT LICENSE
AGREEMENT

THIS AMENDMENT (the "Amendment") is made and entered into as of May
30, 2000 (the "Effective Date"), to the Patent License Agreement
between Pharmacyclics, Inc. ("LICENSEE") and the Board of Regents
("BOARD") of the University of Texas System ("SYSTEM"),
effective May 19, 1992 (the "Agreement," all capitalized terms having
the meanings as defined in the Agreement).

WHEREAS, BOARD and SYSTEM, on behalf of its component institution the
University of Texas at Austin ("UNIVERSITY"), and LICENSEE desire to
enter into this Amendment in order to resolve certain ambiguities in the
original language of the Agreement and to better reflect the parties'
understanding given the development status of the LICENSED SUBJECT MATTER;

NOW, THEREFORE, in consideration of the mutual covenants and agreement of
terms set forth herein, and for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

	Sections 2.8 and 2.10 of the Agreement are deleted in their entirety and
replaced, and new Sections 2.11, 2.12 and 2.13 are added, as follows:

2.8SALE(S), SELL or SOLD shall mean the transfer or disposition of a
LICENSED PRODUCT for value to a party other than LICENSEE, or a SUBSIDIARY or
SUBLICENSEE, but, shall not include any transfer of LICENSED PRODUCT between
LICENSEE and a SUBSIDIARY or SUBLICENSEE.  Goods placed in inventory or on
consignment shall not be deemed SOLD until paid for by an independent third
party purchaser.  SALES shall not include the distribution of reasonable and
customary quantities of complimentary samples and free "trade goods"
including those provided to indigent patient programs.

2.10NET SALES shall mean the gross revenues collected by LICENSEE, its
SUBSIDIARY or SUBLICENSEE from the SALE of LICENSED PRODUCTS during a given
period, less deduction for:

(a)credits or allowances, if any, actually granted on account of price
adjustments, rejection or return of LICENSED PRODUCTS previously SOLD, whether
during the specific period or not, rebates, adjustments and discounts, including
charge backs;

(b)excise or ad valorem taxes, sales, use or other taxes or duties
imposed upon and paid with respect to such sales (excluding franchise, income,
or other taxes levied with respect to gross receipts);

(c)separately itemized insurance and transportation costs incurred in
shipping LICENSED PRODUCTS to independent parties; and

(d)promotional, cash, trade or volume discounts

(such deduction not to exceed the corresponding gross revenues).

2.11SUBLICENSE shall mean a grant, by LICENSEE to an independent third
party that is not a SUBSIDIARY, of the commercial right to manufacture, use or
SELL (including, e.g., marketing, distribution and supply) under the LICENSED
SUBJECT MATTER.

2.12SUBLICENSEE shall mean a party that has been granted a
SUBLICENSE.

2.13SUBLICENSING FEE(S) shall mean payments (in money, or money's worth
as described in Section 5.8(d) herein) received by LICENSEE from a SUBLICENSEE,
which payments are on account of the grant of a SUBLICENSE and are not otherwise
attributable to SALES of LICENSED PRODUCT.  SUBLICENSING FEES excludes payments
in the nature of reimbursements and/or support for future expenditures on
research and development, technology transfer, the transfer of materials for
clinical and other research, manufacturing process development and scale-up and
the like).

B.Section 5.1 of the Agreement is deleted in its entirety and replaced
with the following:

5.1Subject to the other terms of this Article V and in consideration of
rights granted by BOARD to LICENSEE under this Agreement, LICENSEE agrees to pay
BOARD the following:

(a)A running royalty as provided in paragraph 5.2 in the case of SALES by
LICENSEE, its SUBSIDIARIES and/or its SUBLICENSEES.

(b)As payment in full for any and all amounts due BOARD under Section
5.1(b) of the Agreement (prior to the present Amendment), LICENSEE agrees to pay
the following fixed amounts:

	One Hundred Thousand Dollars ($100,000), within thirty (30) days of
LICENSEE's receipt of a fully executed original of this Amendment;
	Fifty Thousand Dollars ($50,000) by August 14, 2001;
	Fifty Thousand Dollars ($50,000) by August 14, 2002;
	Fifty Thousand Dollars ($50,000) by August 14, 2003; and
	Fifty Thousand Dollars ($50,000) by August 14, 2004.

(c)Commencing January 1, 2005 through termination of the Agreement, three
percent (3%) of any SUBLICENSING FEES (less any tax imposed or governmental
charge assessed against such fees) received by LICENSEE in a given calendar
year.  The maximum amount payable to BOARD in any such calendar year on account
of such SUBLICENSING FEES shall not exceed Fifty Thousand Dollars ($50,000).
The amount of SUBLICENSING FEES received in any given calendar year, as used in
calculation of this payment and LICENSEE's corresponding maximum yearly payment
hereunder, shall be re-set to zero at the start of each calendar year; i.e.,
SUBLICENSING FEES in excess of $1.67 Million received in any calendar year
cannot be carried over nor serve as the basis for any payment hereunder in a
subsequent year.

C.Section 5.2 of the Agreement is deleted in its entirety and replaced
with the following:

5.2Subject to Section 5.3, the royalty on SALES shall be:

(a)Five percent (5%) of NET SALES in respect of LICENSED PRODUCTS SOLD
for use as a human therapeutic (including without limitation in radiation or
photodynamic therapy); and

(b)Three percent (3%) of NET SALES in respect of LICENSED PRODUCTS SOLD
for other applications (including without limitation in vitro
inactivation of infectious agents, magnetic resonance imaging (MRI) and in
vitro diagnostics).

D.Section 5.3 of the Agreement is deleted in its entirety and replaced
with the following:

5.3During each calendar year, each royalty rate mentioned in Section
5.2 shall be reduced by one percentage point (1%) for each $15,000,000 in the
aggregate NET SALES of LICENSEE and its SUBSIDIARIES and SUBLICENSES in that
calendar year; provided, however, that no such royalty rate shall be reduced so
as to be less than one (1%) percent.  For example, immediately after the first
$15,000,000 has been achieved during a given calendar year, the rates under
Section 5.2(a) and 5.2(b) will be four percent (4%) and two percent (2%),
respectively.

E.The first sentence of Section 5.7 of the Agreement is deleted in its
entirety and replaced with the following:

5.7During the term of this Agreement and for one (1) year thereafter
LICENSEE shall keep complete and accurate records of its and (as reported to it)
its SUBSIDIARIES' and SUBLICENSES' NET SALES, and of all SUBLICENSING FEES, in
sufficient detail to enable the amounts due BOARD hereunder to be
determined.

F.Section 5.8 of the Agreement is deleted in its entirety and replaced
with the following:

5.8LICENSEE shall provide the following reports and payments to
BOARD.
(a)Within forty-five (45) days after March 31, June 30, September 30 and
December 31, LICENSEE shall deliver to BOARD at the address listed in
paragraph 14.2 a true and accurate report, giving such particulars of the
business conducted by LICENSEE under this Agreement during the previous calendar
quarter as are pertinent to an accounting for payments hereunder, including at
least:  any SUBLICENSING FEE received by LICENSEE, NET SALES received by
LICENSEE and/or its SUBSIDIARIES for each LICENSED PRODUCT, an accounting of any
deduction(s) taken in calculating NET SALES as permitted by the definition
thereof, and the calculation of the total amount owed BOARD hereunder for the
period of such report.  Simultaneously with the delivery of each such report,
LICENSEE shall pay to BOARD the amount, if any, due for the period of such
report.  If no payments are due it shall be so reported.  

(b)LICENSEE shall impose on SUBLICENSEES, mutatis mutandis,
reporting and payment obligations similar to those of Section 5.8(a).  LICENSEE
shall provide to BOARD such similar reports or excerpts therefrom as are
pertinent to an accounting for payments under paragraph 5.1(a), to the extent
received by LICENSEE during a calendar quarter or thereafter up until fifteen
(15) business days prior to the due date for LICENSEE's report under Section
5.8(a).  Simultaneously with the delivery of each such report on SUBLICENSEE
activity, LICENSEE shall pay to BOARD the corresponding royalty amount, if any,
due for the period of such report.  If no payments are due it shall be so
reported.  

(c)Unless otherwise agreed in writing, LICENSEE's royalties hereunder
will be paid in U.S. Dollars as noted in Section 5.10 herein.  Royalties with
respect to amounts other than U.S. Dollars shall be computed in U.S. Dollars by
converting such currency at the average exchange rate for U.S. Dollars
prevailing over the last business day of each month of the calendar quarter
during which the SALES were actually made.  The exchange rates used shall be the
rates published by the Wall Street Journal, and if it does not publish any such
rate or if it is no longer published, a comparable publication to be agreed upon
from time to time by the parties.

(d)For the purposes of Section 5.1(c), the value of any SUB-LICENSING
FEES received other than in money shall be based upon a cash equivalent value to
be agreed upon in good faith between LICENSEE and the BOARD (any value recited
in a corresponding SUB-LICENSE agreement to be accorded significant weight), and
the BOARD's payment therefor shall, upon mutual agreement of BOARD, UNIVERSITY
and LICENSEE, be made in U.S. Dollars or in kind at such agreed-upon value.

G.Section 5.9 of the Agreement is deleted in its entirety and replaced
with the following:

5.9Upon or before each January 1st throughout the term of the
Agreement, LICENSEE shall deliver to BOARD a written report as to LICENSEE's
efforts and accomplishments during the preceding year in commercializing
LICENSED SUBJECT MATTER in the LICENSED TERRITORY, and its commercialization
plans for the coming year.

H.Section 5.10 of the Agreement is deleted in its entirety and replaced
with the following:

5.10All amounts payable hereunder by LICENSEE shall be payable in United
States funds, in accord with Section 5.8(c) herein, without deductions for
taxes, assessments, fees, or charges of any kind unless specifically permitted
under this Agreement.  Checks shall be made payable to "The University of
Texas at Austin" and sent to the UNIVERSITY address noted in Section
14.2.

I.Section 14.2 of the Agreement is deleted in its entirety and replaced
with the following:

14.2Any notice required by this Agreement shall be given in writing by
prepaid, first class, certified mail, return receipt requested, given in person
or given via nationally recognized overnight courier, and shall be effective
upon receipt, addressed as follows:

	
in the case of BOARD, to:
	Board of Regents

The University of Texas System

201 West 7th Street

Austin, Texas  78701

Attention:  Office of General Counsel

	
with a copy to UNIVERSITY at:
	Office of Technology Licensing and Intellectual
Property

The University of Texas at Austin

MCC Building, Suite 1.9A (R3500)

3925 West Braker Lane

Austin, Texas  78701

Attention:  Director

	
in the case of LICENSEE, to:
	Pharmacyclics, Inc.

995 East Arques Avenue

Sunnyvale, California  94086-4521

Attention:  President and CEO

	
with a copy to:
	Pharmacyclics, Inc.

995 East Arques Avenue

Sunnyvale, California  94086-4521

Attention:  Office of General Counsel

or to such other addresses as may be given from time to time under the terms
of this notice provision.

J.In the case of any inconsistency between this Amendment and the
Agreement, this Amendment shall govern.  Except as expressly provided in this
Amendment, all other terms, conditions and provisions of the Agreement shall
continue in full force and effect as provided therein.

IN WITNESS WHEREOF, the LICENSEE and BOARD have executed and delivered this
Amendment, effective as of the date first set forth above.

	
PHARMACYCLICS, INC.
	 	
BOARD OF REGENTS OF THE

UNIVERSITY OF TEXAS SYSTEM

	
By/s/  RICHARD A. MILLIER,
M.D.

Richard A. Miller, M.D.

President and CEO
	 	
By/s/  JUAN M. SANCHEZ, Ph.D.

Juan M. Sanchez, Ph.D.

Vice President for Research

	
Date5/30/00
	 	
Date6/15/00

	 	 	
Approved as to Form:

UNIVERSITY OF TEXAS SYSTEM

	 	 	
ByBETHLYNN MAXWELL, Ph.D.

BethLynn Maxwell, Ph.D.

Office of General Counsel

The University of Texas System

	 	 	
Date6/14/00

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00083-of-00352.parquet"}]]